Early costs and complications of first-line low-grade glioma treatment using a large national database: Limitations and future perspectives

IntroductionDiffuse Low-grade gliomas (DLGG, WHO Grade II) are a heterogenous group of tumors comprising 13–16% of glial tumors. While maximal safe resection is endorsed as the best approach to DLGG, compared to more conservative interventions like stereotactic biopsy, the added costs and risks have...

Full description

Bibliographic Details

Published in:	Frontiers in Surgery
Main Authors:	Kyle Tuohy, Djibril M. Ba, Debarati Bhanja, Douglas Leslie, Guodong Liu, Alireza Mansouri
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-02-01
Subjects:	low-grade glioma (WHO grade II) cost resection stereotactic biopsy adverse events—complications MarketScan database
Online Access:	https://www.frontiersin.org/articles/10.3389/fsurg.2023.1001741/full